Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...
Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a ...
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results